Cornerstone Specialty Network

The largest and most diverse

Independent Network in Community Oncology.

EXPLORE ALL THAT WE HAVE TO OFFER

cornerstoneoncology.com

December 2024

Issue No. 10

Cornerstone’s Network Connection will foster communication across our network and keep members up-to-date on the latest clinical happenings relevant to community oncology as well as Cornerstone events. Click here to review previous newsletters

The Year in Review

CORNERSTONE HAPPENINGS IN 2024

Cornerstone would like to take this opportunity to thank you, our network, for your engagement and participation in our offerings. In the year 2024, we experienced a 50% increase in our in-practice programs. We also expanded our market research programs through Advisory Boards, Practice Patterns and Peer to Peer Insight programs.

Consistent with Cornerstone’s mission to provide value to community oncology practices to help maximize the quality of patient care, Cornerstone hosts virtual in-practice Challenging Cases as an educational initiative with a patient case-based format and peer led moderation. Challenging Cases offer a balanced perspective of the current treatment landscape, consistent with FDA and NCCN Guidelines, and provides an opportunity for peer-to peer exchange. Click here to access previous Challenging Cases

Cornerstone’s National Fall Summit was held in Las Vegas on October 18th and 19th with 45 network members in attendance.The 2-day event provided a chance to discuss changes in the oncology landscape, an opportunity to learn about CSN value offerings and how they support independence in community oncology, as well as best practices to create long-term, sustainable value for practices. Edith A. Perez, M.D., Cornerstone’s Medical Director and Professor Emeritus at Mayo Clinic, along with representatives from Viz.AI, discussed the timely topic of “The Evolving Role of AI in Community Oncology”.

Our ESMO Symposium was held virtually on October 24, 2024, with our cochairs Dr. Edith Perez, Dr. Sujith Kalmadi, and Dr. Eric Schaefer highlighting practice changing trials from the ESMO 2024 Congress as well as key updates from WCLC 2024 and a review of data leading to recent FDA approvals. Click here to access the presentation slides and videos

Our virtual ASCO Symposium was held on July 18, 2024 with Dr. Edith Perez, Dr. Eric Schaefer, and Dr. Sujith Kalmadi highlighting the top practice changing clinical data presented at the 2024 ASCO Annual Meeting held in Chicago from May 31 – Jun 4, 2024. Key areas of discussion included HER2-low and -ultralow breast cancer, EGFR-mutated NSCLC, and melanoma with additional content covered in rapid reviews. Click here to access the presentation slides and video

Community oncology fellowship advancement initiative (COFAI): Specifically customized for future leaders of community oncology with the goal of accelerating quality patient care. COFAI is an exclusive series of educational web conferences that launched in June 2022. Course content is created by community-based oncology practice leaders who have unique medical and practice management perspectives. Learn More

Click here to sign up for COFAI information

Cornerstone Team

A focus on delivering value to community oncology requires a full-time team of experts with combined extensive experience in practice support, value program development, pharma and private business operations. Cornerstone is growing to meet the needs of our Network. Click here to meet our team members

Practice Spotlight

Our Practice Spotlight focuses on individual practices in our network. The spotlight article allows our practices to comment on the state of oncology and reflect on some of the biggest challenges facing independent oncology practices today.

Utah Cancer Specialists

Northwest Cancer Centers

Physician Spotlight

Our Physician Spotlight encourages physicians in our network to share their philosophy and discuss the advances in oncology that they are most excited about, as well as the Cornerstone programs that they find beneficial.

Dr. Kimberly Ku

CORNERSTONE GOALS FOR 2025

Looking ahead to 2025, Cornerstone Specialty Network's goal is to continue to deliver a high quality product that is deemed meaningful in the marketplace. We plan to continue to expand and strengthen our network of 50+ unique practices. We will be launching data driven projects, clinical investigation projects as well as continuing to evaluate other value-added offerings. Our goal is to evolve so we can continue to provide VALUE to you, our community-based oncology practices, so that, in turn, you can continue to maximize your quality of patient care.

2025 UPCOMING EVENTS

Spring Summit
Symposia
SABCS in January
ASH in February
Lung in May
ASCO in July
Nurse in August
ESMO in December
Challenging Cases

Upcoming Events

CLINICAL UPDATES

FDA Updates for November 2024

On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC) based on the HERIZON-BTC-01 trial (NCT04466891). The FDA also approved VENTANA PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc./Roche Diagnostics) as a companion diagnostic device to aid in identifying patients with BTC who may be eligible for treatment with Ziihera. Read More

On November 19, 2024, the FDA approved updated drug labeling for fludarabine phosphate (Fludarabine Phosphate Injection, Sandoz) under Project Renewal, an Oncology Center of Excellence (OCE) initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date. Fludarabine Phosphate Injection is now approved as a component of a combination regimen for the treatment of adults with B-cell chronic lymphocytic leukemia (CLL), and for the treatment of adults with B-cell CLL who have not responded to or whose disease has progressed during treatment with at least one alkylating-agent containing regimen. Additional labeling revisions include a revised and updated dosage regimen to include the recommended dosage for use in combination with cyclophosphamide and rituximab, and the boxed warning was removed, and this information was incorporated in the Warnings and Precautions section. Read More

On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older based on the AUGMENT-101 trial (NCT04065399). Read More

On November 8, 2024, the FDA approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) based on the FELIX trial (NCT04404660). Read More

According to Forbes Health, 62% of people say they feel pressured to set a New Year’s resolution. However, maintaining those resolutions is a different story. Most people keep their resolutions for two to three months, with only 1% making it to a year. Therefore, experts recommend setting resolutions that are both meaningful and achievable. Planning and asserting your goals is the first step to achieving them.

We aim to keep our (CSN) resolution to provide value to the network.

Do you keep your New Year resolutions?

Yes, always

Only for a month or so

Too busy helping patients!

The tally results will appear in the January newsletter.

Cornerstone Partners

Thank You

Cornerstone would like to take this opportunity to thank our select pharma partners for their support of our programs enabling us to provide unique opportunities to connect with our network, deliver key educational programs, and ultimately benefit patient care.

WELLNESS PRODUCTS & EDUCATION

wellCORNER

Provide your patients access to medically reviewed, high-quality wellness products. wellCORNER can serve as your practice’s offering to patients on wellness products and education.

Why wellCORNER? Learn More

Marketing Materials available upon request. Email info@wellCORNER.com

Explore wellCORNER.com

Cornerstone Specialty Network LLC • P.O. Box 173, New Hope, PA

www.cornerstoneoncology.com